Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014 (2014), Article ID 973139, 8 pages
Research Article

Evidences of +896 A/G TLR4 Polymorphism as an Indicative of Prevalence of Complications in T2DM Patients

1Department of Pathobiology and Medical and Forensic Biotechnologies, University of Palermo, Tukory’s Street 211, 90134 Palermo, Italy
2Metabolic Diseases and Diabetology Unit, Italian National Research Center on Aging (INRCA), Ancona, Italy
3Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
4Center of Clinical Pathology and Innovative Therapy, Italian National Research Center on Aging (INRCA), Ancona, Italy
5Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
6Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain
7Department of Cardiovascular and Metabolic Diseases, IRCCS Gruppo Multimedica, Sesto San Giovanni (MI), Italy
8Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, CNR-ISOF and IRCCS Neuroscience, Bologna, Italy
9Biostatistical Center, Italian National Research Center on Aging (INRCA), Ancona, Italy
10Experimental Models in Clinical Pathology, Italian National Research Center on Aging (INRCA), Ancona, Italy

Received 23 January 2014; Accepted 6 March 2014; Published 2 April 2014

Academic Editor: José Cesar Rosa

Copyright © 2014 Carmela Rita Balistreri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


T2DM is today considered as world-wide health problem, with complications responsible of an enhanced mortality and morbidity. Thus, new strategies for its prevention and therapy are necessary. For this reason, the research interest has focused its attention on TLR4 and its polymorphisms, particularly the rs4986790. However, no conclusive findings have been reported until now about the role of this polymorphism in development of T2DM and its complications, even if a recent meta-analysis showed its T2DM association in Caucasians. In this study, we sought to evaluate the weight of rs4986790 polymorphism in the risk of the major T2DM complications, including 367 T2DM patients complicated for the 55.6%. Patients with A/A and A/G TLR4 genotypes showed significant differences in complication’s prevalence. In particular, AG carriers had higher risk prevalence for neuropathy (), lower limb arteriopathy (), and the major cardiovascular pathologies (). Their cumulative risk was significant (), with a threefold risk to develop neuropathy, lower limb arteriopathy, and major cardiovascular events in AG cases compared to AA cases. The adjusted OR for the confounding variables was 3.788 (95% CI: 1.642–8.741). Thus, the rs4986790 polymorphism may be an indicative of prevalence of complications in T2DM patients.